Spots Global Cancer Trial Database for nasopharyngeal neoplasms
Every month we try and update this database with for nasopharyngeal neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0) | NCT00563862 | Nasopharyngeal ... Carcinoma, Squa... | Conventional RT Accelerated RT Cisplatin 5-fluorouracil | - 70 Years | Hospital Authority, Hong Kong | |
| Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer | NCT00078494 | Nasopharyngeal ... | EBV-LMP-2 | - | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients | NCT02505139 | Nasopharyngeal ... | the number of c... | 18 Years - 65 Years | Sun Yat-sen University | |
| Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma | NCT02211677 | Nasopharyngeal ... Blood Cell Coun... Neoplasm Stagin... Prognosis | 18 Years - 75 Years | Sun Yat-sen University | ||
| Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma | NCT02360501 | Nasopharyngeal ... | Docetaxel Cisplatin Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients | NCT02505139 | Nasopharyngeal ... | the number of c... | 18 Years - 65 Years | Sun Yat-sen University | |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
| A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma | NCT02444949 | Nasopharyngeal ... | endostar intensity modul... cisplatin | 18 Years - 70 Years | China Three Gorges University, Yichang, China | |
| Modified Vaccinia Ankara (MVA) Vaccine Study | NCT01256853 | Nasopharyngeal ... Epstein-Barr Vi... | MVA Vaccine | 18 Years - | Chinese University of Hong Kong | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery | NCT03010813 | Colorectal Neop... Urologic Neopla... Urologic Diseas... Nasopharyngeal ... Oropharyngeal N... Oral Neoplasms Hypopharyngeal ... Laryngeal Neopl... ENT Diseases | Robotic single ... | 18 Years - | Chinese University of Hong Kong | |
| Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0) | NCT00563927 | Nasopharyngeal ... Carcinoma, Squa... | Conventional RT Cisplatin 5-fluorouracil | - 70 Years | Hospital Authority, Hong Kong | |
| Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer | NCT00078494 | Nasopharyngeal ... | EBV-LMP-2 | - | National Institutes of Health Clinical Center (CC) | |
| Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma | NCT02250599 | Nasopharyngeal ... | Paclitaxel Bevacizumab Carboplatin | 18 Years - | Sun Yat-sen University | |
| A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application | NCT02980315 | Nasopharyngeal ... | CAR-T cells | - | The Second Hospital of Nanjing Medical University | |
| Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma | NCT02360501 | Nasopharyngeal ... | Docetaxel Cisplatin Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma | NCT04870905 | Nasopharyngeal ... | Tis-U-Sol | 18 Years - 65 Years | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | NCT00747799 | Nasopharyngeal ... | Sorafenib plus ... | 18 Years - | Sun Yat-sen University | |
| Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT05807880 | Nasopharyngeal ... | The combination... | 18 Years - 65 Years | Sun Yat-sen University | |
| A Trial of Endostar in Patients With Carcinoma of the Head and Neck | NCT02902432 | Nasopharyngeal ... | Endostar | 18 Years - 70 Years | China International Medical Foundation | |
| Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma. | NCT02456506 | Nasopharyngeal ... Mortality Quality of Life Complications | Hyperfractionat... Conventional Fr... | 18 Years - 65 Years | Sun Yat-sen University | |
| The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | NCT01797900 | Nasopharyngeal ... | Cisplatin Paclitaxel IMRT | 18 Years - 70 Years | ChineseAMS | |
| Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma | NCT03093649 | Nasopharyngeal ... | adverse events ... do not report a... | 18 Years - | Sun Yat-sen University | |
| ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy | NCT02874651 | Nasopharyngeal ... | Apatinib Placebo | 18 Years - 70 Years | Sun Yat-sen University | |
| Taxotere + Cisplatin in Nasopharyngeal Carcinoma | NCT00436293 | Nasopharyngeal ... | Docetaxel Cisplatin | 18 Years - | Sanofi | |
| Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma | NCT02360501 | Nasopharyngeal ... | Docetaxel Cisplatin Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT | NCT02735317 | Nasopharyngeal ... Stomatitis | Oral Ulcer Garg... Quadruple mixtu... | 18 Years - 65 Years | Sun Yat-sen University | |
| Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy | NCT00630149 | Nasopharyngeal ... | Pemetrexed (Ali... | 18 Years - | Sun Yat-sen University | |
| Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma | NCT02250599 | Nasopharyngeal ... | Paclitaxel Bevacizumab Carboplatin | 18 Years - | Sun Yat-sen University | |
| Family Study of Head and Neck Cancers in Taiwan | NCT00342147 | Nasopharyngeal ... Herpesvirus 4, ... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma | NCT03700476 | Nasopharyngeal ... | Sintilimab Gemcitabine Cisplatin intensity-modul... | 18 Years - 65 Years | Sun Yat-sen University | |
| Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma. | NCT02456506 | Nasopharyngeal ... Mortality Quality of Life Complications | Hyperfractionat... Conventional Fr... | 18 Years - 65 Years | Sun Yat-sen University | |
| Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer | NCT00577057 | Nasopharyngeal ... | Conventional Ra... Accelerated Rad... Cisplatin 5-fluorouracil Capecitabine | 18 Years - 70 Years | Hospital Authority, Hong Kong | |
| Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma | NCT03180476 | Nasopharyngeal ... | Apatinib | 18 Years - 75 Years | Sichuan Cancer Hospital and Research Institute | |
| Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma | NCT01735409 | Nasopharyngeal ... | ABX + DDP ABX + DDP ABX + DDP | 18 Years - | Sun Yat-sen University | |
| Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0) | NCT00563927 | Nasopharyngeal ... Carcinoma, Squa... | Conventional RT Cisplatin 5-fluorouracil | - 70 Years | Hospital Authority, Hong Kong | |
| Intensity Modulated Radiation Therapy for Head and Neck Cancer | NCT00188877 | Nasopharyngeal ... | intensity modul... cisplatinium an... | 18 Years - 70 Years | University Health Network, Toronto | |
| IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. | NCT03854838 | Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Head and Neck N... | Tolipalimab Reirradiation | 18 Years - 65 Years | Sun Yat-sen University | |
| Environmental and Genetic Determinants of NPC | NCT01257100 | Nasopharyngeal ... Herpesvirus 4, ... | 21 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma | NCT03427827 | Nasopharyngeal ... | Camrelizumab | 18 Years - 65 Years | Sun Yat-sen University | |
| Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma | NCT02945878 | Nasopharyngeal ... Stomatitis | 18 Years - 70 Years | Zhejiang Cancer Hospital | ||
| Nivolumab in Children and Adults With Nasopharyngeal Carcinoma | NCT06019130 | Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Nasopharynx Can... | Nivolumab Cisplatin 5-Fluorouracil Gemcitabine Radiotherapy Interferon beta... MRI PET Patient-Reporte... | 3 Years - | German Society for Pediatric Oncology and Hematology GPOH gGmbH | |
| Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents | NCT00565448 | Nasopharyngeal ... Carcinoma | docetaxel cisplatin 5-fluorouracil | 1 Month - 21 Years | Sanofi | |
| Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0) | NCT00563862 | Nasopharyngeal ... Carcinoma, Squa... | Conventional RT Accelerated RT Cisplatin 5-fluorouracil | - 70 Years | Hospital Authority, Hong Kong | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma | NCT01528618 | Nasopharyngeal ... | gemcitabine and... 5-Fluorouracil ... | 18 Years - | Sun Yat-sen University | |
| GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma | NCT03840421 | Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Head and Neck N... | gemcitabine and... cisplatin and f... IMRT cisplatin | 18 Years - 65 Years | Sun Yat-sen University | |
| A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma | NCT02444949 | Nasopharyngeal ... | endostar intensity modul... cisplatin | 18 Years - 70 Years | China Three Gorges University, Yichang, China | |
| Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | NCT00747799 | Nasopharyngeal ... | Sorafenib plus ... | 18 Years - | Sun Yat-sen University | |
| Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma | NCT03837808 | Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Head and Neck N... | Nimotuzumab Cisplatin | 18 Years - 70 Years | Sun Yat-sen University | |
| Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) | NCT02611960 | Nasopharyngeal ... | Pembrolizumab Capecitabine Gemcitabine Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | NCT03769467 | Nasopharyngeal ... Nasopharyngeal ... Epstein-Barr Vi... Epstein-Barr Vi... Epstein-Barr Vi... | tabelecleucel pembrolizumab | 12 Years - | Atara Biotherapeutics | |
| Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy | NCT00630149 | Nasopharyngeal ... | Pemetrexed (Ali... | 18 Years - | Sun Yat-sen University | |
| The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients | NCT02505139 | Nasopharyngeal ... | the number of c... | 18 Years - 65 Years | Sun Yat-sen University | |
| Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma | NCT03837808 | Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Head and Neck N... | Nimotuzumab Cisplatin | 18 Years - 70 Years | Sun Yat-sen University | |
| Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma | NCT00436800 | Nasopharyngeal ... | Gemcitabine Oxaliplatin | 18 Years - | Sanofi | |
| Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma | NCT03093649 | Nasopharyngeal ... | adverse events ... do not report a... | 18 Years - | Sun Yat-sen University | |
| Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma | NCT05807880 | Nasopharyngeal ... | The combination... | 18 Years - 65 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
